



Docket No. 75723-ZB/JPW/GJG/CS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: David Baltimore et al.

Serial No.: 10/037,415 Examiner: C. Hibbert

Filed : January 4, 2002 Group Art Unit: 1636

For : NUCLEAR FACTORS ASSOCIATED WITH TRANSCRIPTIONAL
REGULATION

30 Rockefeller Plaza
20th Floor
New York, New York 10112
February 23, 2008

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, Applicants direct the Examiner's attention to the following disclosures, which are also listed on the attached substitute Form PTO-1449 (**Exhibit A**).

The subject application is a continuation under 35 U.S.C. § 120 of U.S. Application No. 08/464,364, filed June 5, 1995, now U.S. Patent No. 6,410,516, issued June 25, 2002, now undergoing reexamination under Control Nos. 90/007,503 and 90/007,828 which have been previously disclosed and brought to the Examiner's attention in the subject application.

Applicants note that item 1 listed herein is part of the merged *Ex Parte* Reexamination Control Nos. 90/007,503 and 90/007,828. Items 2-3 listed herein are part of a concurrent litigation captioned *Amgen Inc., et al. v. ARIAD Pharmaceuticals, Inc., et al.* The merged reexamination and

02/26/2009 10000037 10037415
00000037 10037415
100.00 00
00 00:1000

Applicants : David Baltimore et al.

Serial No. : 10/037,415

Filed : January 4, 2002

Page 2 of 4 of Supplemental Information Disclosure Statement

the concurrent litigation proceedings involve U.S. Patent No. 6,410,516, which issued from a parent of the subject application.

All disclosures are readily available to the Examiner and to the public from the file history of U.S. Patent No. 6,410,516 and its merged reexamination proceeding (*Ex Parte Reexamination Control Nos. 90/007,503, filed April 4, 2005, and 90/007,828, filed December 2, 2005*). Accordingly, copies of items 1-3 are not enclosed.

The Examiner is respectfully requested to make the items of record in the subject application by initialing and dating the attached substitute Form PTO-1449, and returning a copy of the initialed and dated form to Applicants' undersigned attorneys.

1. Advisory Action issued February 14, 2009 in Merged Reexamination Control Nos. 90/007,503 and 90/007,828;
2. Brief of Plaintiffs/Counterclaim Defendants-Appellees Amgen Inc., et al., filed January 28, 2009 in the concurrent litigation captioned *Amgen Inc., et al. v. ARIAD Pharmaceuticals, Inc., et al.*, U.S. Court of Appeals for the Federal Circuit, Docket No. 2009-1023; and
3. Reply Brief for Appellants, ARIAD Pharmaceuticals, Inc., et al., filed February 17, 2009 in the concurrent litigation captioned *Amgen Inc., et al. v. ARIAD Pharmaceuticals, Inc., et al.*, U.S. Court of Appeals for the Federal Circuit, Docket No. 2009-1023.

Item 1 was issued February 14, 2009 in connection with merged *Ex Parte Reexamination Control Nos. 90/007,503 and 90/007,828*.

Applicants : David Baltimore et al.

Serial No. : 10/037,415

Filed : January 4, 2002

Page 3 of 4 of Supplemental Information Disclosure Statement

Items 2-3 was previously disclosed as Exhibits 1-2 in SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT, filed February 23, 2009, in connection with merged *Ex Parte* Reexamination Control Nos. 90/007,503 and 90/007,828.

This Supplemental Information Disclosure Statement is being submitted under 37 C.F.R. §1.97(c)(2), before the mailing of a Final Office Action. Accordingly, Applicants enclose a check in the amount of ONE HUNDRED AND EIGHTY DOLLARS (\$180.00) for filing this Supplemental Information Disclosure Statement.

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

Applicants : David Baltimore et al.


Serial No. : 10/037,415

Filed : January 4, 2002

Page 4 of 4 of Supplemental Information Disclosure Statement

No fee, other than the enclosed \$180.00 fee for filing a Supplemental Information Disclosure Statement, is deemed necessary in connection with filing this Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the additional amount of any such fee to Deposit Account No. 03-3125.


Respectfully submitted,



John P. White
Registration No. 28,678
Gary J. Gershik
Registration No. 39,992
Attorneys for Applicants
Cooper & Dunham LLP
30 Rockefeller Plaza
20th Floor
New York, New York 10112
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


John P. White
Reg. No. 28,678
Gary J. Gershik
Reg. No. 39,992

Date

EXHIBIT A

of Supplemental Information Disclosure Statement

Applicants: David Baltimore, et al.
Serial No.: 10/037,415
Filed: January 4, 2002
Group Art Unit: 1636
Examiner: C. Hibbert